CIL 004
Alternative Names: CIL-004Latest Information Update: 29 May 2024
At a glance
- Originator Sanofi
- Developer Cilcare
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Otitis
Most Recent Events
- 29 May 2024 Cilcare has patent protection for CIL 004, before May 2024 (Cilcare website, May 2024)
- 29 May 2024 Preclinical trials in Otitis in France (unspecified route), before May 2024 (Cilcare pipeline, May 2024)